CN1249085C - 诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽 - Google Patents

诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽 Download PDF

Info

Publication number
CN1249085C
CN1249085C CNB018100058A CN01810005A CN1249085C CN 1249085 C CN1249085 C CN 1249085C CN B018100058 A CNB018100058 A CN B018100058A CN 01810005 A CN01810005 A CN 01810005A CN 1249085 C CN1249085 C CN 1249085C
Authority
CN
China
Prior art keywords
peptide
xaa
amyloid
seq
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018100058A
Other languages
English (en)
Chinese (zh)
Other versions
CN1444598A (zh
Inventor
B·弗朗吉诺
T·维希涅夫斯基
E·M·西于尔兹松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of CN1444598A publication Critical patent/CN1444598A/zh
Application granted granted Critical
Publication of CN1249085C publication Critical patent/CN1249085C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018100058A 2000-05-22 2001-05-22 诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽 Expired - Fee Related CN1249085C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20557800P 2000-05-22 2000-05-22
US60/205,578 2000-05-22

Publications (2)

Publication Number Publication Date
CN1444598A CN1444598A (zh) 2003-09-24
CN1249085C true CN1249085C (zh) 2006-04-05

Family

ID=22762767

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018100058A Expired - Fee Related CN1249085C (zh) 2000-05-22 2001-05-22 诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽

Country Status (14)

Country Link
US (3) US6713450B2 (cg-RX-API-DMAC7.html)
EP (1) EP1284998B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003534351A (cg-RX-API-DMAC7.html)
CN (1) CN1249085C (cg-RX-API-DMAC7.html)
AT (1) ATE286072T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001274873B2 (cg-RX-API-DMAC7.html)
CA (1) CA2408925A1 (cg-RX-API-DMAC7.html)
DE (1) DE60108111T2 (cg-RX-API-DMAC7.html)
ES (1) ES2238049T3 (cg-RX-API-DMAC7.html)
IL (2) IL152625A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ521939A (cg-RX-API-DMAC7.html)
PT (1) PT1284998E (cg-RX-API-DMAC7.html)
WO (1) WO2001090182A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207992B (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20040191264A1 (en) * 2001-02-19 2004-09-30 Nielsen Klaus Gregorius Synthetic vaccine agents
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
WO2002074931A2 (en) * 2001-03-20 2002-09-26 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2493119A1 (en) * 2002-07-17 2004-01-22 Mindset Biopharmaceuticals Usa Inc. Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
US7476509B2 (en) * 2002-11-14 2009-01-13 Adherex Technologies Inc. Compounds and methods for modulating functions of nonclassical cadherins
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0310270D0 (en) * 2003-05-03 2003-06-11 Univ Edinburgh Biomolecular devices
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
KR20070100234A (ko) * 2004-10-06 2007-10-10 히로시 모리 변이형 아밀로이드 단백질
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8470325B2 (en) * 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
WO2008099920A1 (ja) * 2007-02-15 2008-08-21 Kyushu University, National University Corporation 抗hmgb-1抗体を含む間質性肺疾患治療剤
JP5285437B2 (ja) * 2007-02-15 2013-09-11 学校法人福岡大学 抗hmgb−1抗体を含む臓器移植拒絶抑制剤
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008106657A2 (en) * 2007-03-01 2008-09-04 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β-類澱粉蛋白之基原纖維形式具專一性之抗體
US8409584B2 (en) * 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN101920008B (zh) * 2009-06-15 2013-07-31 浙江仙琚制药股份有限公司 包含Aβ40多肽和铝佐剂的制剂以及纯化Aβ40多肽的方法
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
US11970521B2 (en) * 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760676B1 (en) * 1994-05-25 2001-07-11 McMICHAEL, John Materials and methods for treatment of plaquing diseases
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE69831971T2 (de) 1997-12-03 2006-07-06 Neuralab Ltd., Flatts Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Also Published As

Publication number Publication date
DE60108111D1 (de) 2005-02-03
JP2003534351A (ja) 2003-11-18
WO2001090182A3 (en) 2002-05-23
US7700107B2 (en) 2010-04-20
US7427655B2 (en) 2008-09-23
PT1284998E (pt) 2005-06-30
EP1284998B1 (en) 2004-12-29
US20020077288A1 (en) 2002-06-20
US20090081204A1 (en) 2009-03-26
AU7487301A (en) 2001-12-03
CN1444598A (zh) 2003-09-24
US6713450B2 (en) 2004-03-30
ES2238049T3 (es) 2005-08-16
DE60108111T2 (de) 2005-12-08
NZ521939A (en) 2004-04-30
IL152625A (en) 2009-12-24
ZA200207992B (en) 2003-07-02
WO2001090182A2 (en) 2001-11-29
US20040043935A1 (en) 2004-03-04
CA2408925A1 (en) 2001-11-29
ATE286072T1 (de) 2005-01-15
EP1284998A2 (en) 2003-02-26
IL152625A0 (en) 2003-06-24
AU2001274873B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CN1444598A (zh) 诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽
CN1279971C (zh) 下调淀粉状蛋白的新方法
CN1259340C (zh) 作为免疫原治疗过敏症的肽组合物
CN1568329A (zh) 一种用于预防和治疗阿尔兹海默氏病的具有免疫原性的肽组合物
CN1646559A (zh) 治疗阿尔茨海默氏病的免疫学方法及组合物
CN1541225A (zh) 识别β淀粉样肽的人源化抗体
CN1213380A (zh) 用于预防和治疗过敏的肽免疫原
AU2001274873A1 (en) Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
CN1118474C (zh) 合成肽及包含其的疫苗
CN1685236A (zh) N-11端截短的β-淀粉样蛋白的单克隆抗体、组合物、方法和用途
CN1934127A (zh) Αβ免疫原性肽载体-偶联物及其生产方法
CN101043901A (zh) 预防和治疗阿尔茨海默病的方法
CN1659187A (zh) 融合铁蛋白在疫苗和其他方面的应用
CN1303394A (zh) 用于预防和治疗hiv感染和免疫疾病的肽组合物
CN1359301A (zh) 致淀粉样病的预防和治疗
CN1146772A (zh) 用于治疗过敏反应的合成肽免疫原
CN1167491A (zh) 用于治疗变态反应的合成IgE膜锚肽免疫原
CN101052417A (zh) 突触核蛋白病以及淀粉样变性病的预防和治疗
CN1714153A (zh) 重组蛋白质变异体
CN121001737A (zh) Tau和β淀粉样肽免疫原组合物及相关方法
CN1204253C (zh) 奈瑟氏球菌乳铁蛋白结合蛋白
CN101052718A (zh) 变异型淀粉样蛋白质
CN1768079A (zh) 多肽
CN1492926A (zh) 神经丝蛋白的优选区段及其使用方法
CN1893970A (zh) β-淀粉样蛋白-类似物-T-细胞表位疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee